A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors
Recruiting in Palo Alto (17 mi)
JL
Overseen byJin Li
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Recruiting
Sponsor: I-Mab Biopharma US Limited
No Placebo Group
Trial Summary
What is the purpose of this trial?
A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors
Research Team
JL
Jin Li
Principal Investigator
Shanghai East Hospital
Eligibility Criteria
Inclusion Criteria
Both male and female aged 18 or above;
ECOG score: 0-1;
The subjects voluntarily participate in the study, sign the Informed Consent Form, with good compliance, and can cooperate with the follow-up.
See 7 more
Treatment Details
Interventions
- TJ210001 Injection (Unknown)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: TJ210001 InjectionExperimental Treatment1 Intervention
Single Arm Dose expansion
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Loading ...
Who Is Running the Clinical Trial?
I-Mab Biopharma US Limited
Lead Sponsor
Trials
10
Patients Recruited
580+
Headquarters
Rockville, USA
Known For
Precision Medicine
Top Products
TJ202 (Felzartamab), TJ101 (Eftansomatropin), Enoblituzumab
I-Mab Biopharma Co. Ltd.
Lead Sponsor
Trials
22
Patients Recruited
2,500+
Founded
No information found
Headquarters
Rockville, USA
Known For
Precision Immuno-Oncology
Top Products
TJ202 (Felzartamab), TJ101 (Eftansomatropin), Enoblituzumab, TJ107